Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Century Therapeutics, Inc. (IPSC:NASDAQ), powered by AI.
Century Therapeutics, Inc. is currently trading at $2.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Century Therapeutics, Inc. on Alpha Lenz.
View Century Therapeutics, Inc.'s valuation metrics on Alpha Lenz.
“Century Therapeutics, Inc.'s ROE is -6.0%. Explore profitability and growth together.”
Ask for details →Century Therapeutics Inc. is a biotechnology company that focuses on developing innovative cell therapies for cancer treatment. The company's core mission centers around harnessing the potential of induced pluripotent stem cells (iPSCs) to create highly effective, off-the-shelf cellular therapies. By leveraging iPSCs, Century Therapeutics aims to produce uniformly engineered allogeneic cell products designed to target and eliminate cancer cells with precision. Century Therapeutics operates primarily within the healthcare and biopharmaceutical industry, specifically targeting the oncology sector. It seeks to address unmet medical needs by offering more accessible and potent therapeutic solutions compared to traditional cancer treatments. The company's research and development efforts are focused on using its technology platform to generate natural killer (NK) cells and T cells that possess enhanced tumor-fighting capabilities. In the financial market, Century Therapeutics plays a vital role in driving innovation in cancer treatment solutions. It represents a segment of biotechnology firms dedicated to advancing cellular immunotherapies, potentially transforming the landscape of cancer care and treatment. The company's work contributes to the growing field of cell therapy, highlighting the importance of biotechnological advances in modern medicine.
“Century Therapeutics, Inc.'s ROE is -6.0%. Explore profitability and growth together.”
Ask for details →Century Therapeutics, Inc. (ticker: IPSC) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 140 employees.
The current price is $2.25 with a P/E ratio of -x and P/B of -x.
ROE is -5.98% and operating margin is -9.62%. Annual revenue is $109M.